GSK’s Cancer Drug Jemperli Nears EU Marketing Expansion
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
Daily3d
Jemperli bags USFDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer: GSK
London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...
MarketWatch3d
GSK's Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission -- Update
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency. The British pharmaceutical giant said Monday that the ...
腾讯网12h
“史无前例！”100%患者持久无癌超2年，GSK单抗一线疗法获FDA突破性疗法认定
▎药明康德内容团队编辑GSK日前宣布，美国FDA已授予其PD-1抑制剂Jemperli（dostarlimab）用于治疗局部晚期错配修复缺陷（dMMR）/高微卫星不稳定性（MSI-H）直肠癌的突破性疗法认定（BTD）。根据新闻稿，这是dostarli ...
London South East3d
Jemperli receives positive CHMP opinion
Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary advanced or recurrent endometrial cancer · Positive opinion based ...
GSK的Jemperli获得CHMP对子宫内膜癌治疗的积极意见
在日本，GSK的呼吸道合胞病毒（RSV）疫苗Arexvy已获批用于50-59岁成年人。公司还报告了linerixibat的第三阶段GLISTEN试验的积极结果，该药物旨在治疗原发性胆汁性胆管炎患者的胆汁淤积性瘙痒。然而，由于预期2025年增长将趋于平缓，Jefferies和Guggenheim的金融分析师已下调了GSK的股票评级。
Wall Street Journal3d
GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission
GSK’sGSK-0.41%decrease; red down pointing triangle cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency.
GSK's Cancer Drug Jemperli Nears EU Marketing Expansion -- 2nd Update
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.
GSK的Jemperli获得FDA突破性疗法认定用于治疗直肠癌
Jemperli是一种抗PD-1抗体，是GSK免疫肿瘤学研究和开发的基础。它目前在美国获批用于某些类型的子宫内膜癌，并在加速批准下用于dMMR复发或晚期实体瘤，继续批准取决于确证性试验的验证。本报告基于GSK plc的新闻稿。